Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid<sup>®</sup>) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty<sup>®</sup>)
A recombinant SARS-CoV-2 spike protein vaccine (NVX-CoV2373) has been licensed and has a lesser incidence of adverse events. To know the immunological mechanisms of adverse events, the production of cytokines and chemokines was investigated in mice inoculated with NVX-CoV2373. Serum IL-6 was detecte...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/11/1677 |